Compare ECOR & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECOR | PDSB |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1M | 49.5M |
| IPO Year | 2018 | N/A |
| Metric | ECOR | PDSB |
|---|---|---|
| Price | $7.34 | $0.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $22.00 | $9.00 |
| AVG Volume (30 Days) | 97.1K | ★ 857.6K |
| Earning Date | 03-11-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,835,000.00 | N/A |
| Revenue This Year | $28.92 | N/A |
| Revenue Next Year | $40.87 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 27.90 | N/A |
| 52 Week Low | $4.16 | $0.70 |
| 52 Week High | $19.49 | $2.20 |
| Indicator | ECOR | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 46.86 |
| Support Level | $6.40 | $0.86 |
| Resistance Level | $8.30 | $1.01 |
| Average True Range (ATR) | 0.86 | 0.09 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 71.53 | 14.51 |
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.